



GV-SOLAS

Gesellschaft für Versuchstierkunde
Society for Laboratory Animal Science

Expert Information

From the Working Group on Hygiene

**Implication of infectious agents on
results of animal experiments**

Kilham Rat Virus

Status December 2021

Authors: GV-SOLAS Working Group on Hygiene

Contents

Background	3
Prevalence	3
Host species.....	3
Properties.....	3
Susceptibility	4
Organotropism.....	4
Clinical disease	4
Pathology	4
Morbidity and mortality	5
Zoonotic potential	5
Interference with research	5
<i>Oncology</i>	5
<i>Teratology</i>	5
<i>Infectiology / Interactions with other infectious agents</i>	5
<i>Immunology</i>	5
<i>Toxicology</i>	5
<i>Physiology</i>	6
<i>Cell biology</i>	6
<i>Assisted reproductive technology</i>	6
Special considerations.....	6
References.....	7

Kilham Rat Virus (KRV)

Background

- First described by Kilham and Olivier in 1959.¹
- Belongs to the family Parvoviridae²
- Synonymous with Rat Virus (RV) and parvovirus r-1²
- Single stranded (ss) DNA-virus^{2,3}
- Virion non-enveloped²

Prevalence

- Prevalence (serological) was high in rat colonies; although only few outbreaks of disease were reported; therefore, KRV was considered a significant pathogen.²
- A serological survey of laboratory rats in Western Europe facilities in 2009 resulted in a prevalence of parvoviruses in rats of 12.1%, of which Kilham Rat Virus was present with 12.45%.⁴
- Another survey of more than 80'000 serological rat samples from North America and Europe over several years reported in 2009 a prevalence of KRV of 1.30% in total (1.23% North America, 4.05% Europe).⁵
- In Argentina, a serological prevalence of KRV was detected between 27.8 and 75% in conventional animal facilities.⁶

Host species

- Wild and laboratory rats are the natural hosts of the virus.^{2,3}

Properties

- Transmission primarily via horizontal route through direct contact or fomites^{2,3}
- Virus is shed via urine, faeces, milk and nasal secretions^{2,3}; transmission via milk seems not to produce lethal doses for offspring.⁷
- Efficiency of transmission depends on strain of virus and age of rats at timepoint of infection.²
- Transplacental transmission was suggested but remains questionable^{2,3}, although in utero infection was shown through litter exchange experiments by Novotny and Hetrick.⁷
- Experimental transmission is possible via oronasal route in juvenile (4 weeks) and infant (2 days) rats and leads to infection.⁸
- Virus may persist for varying times after natural and experimental infection, the longer the earlier in life infection occurs.^{3,8,9,10,11,12}
- Persistent infection is also described in athymic or T cell-deficient rats.^{3,12,13}
- Can cause persistent infection of cell lines and transplantable tumours; transmission through contaminated cells and tumours is an important route of infection.²
- Resistant to environmental conditions (such as high temperature; infectivity retained after heating at 80°C for 2hr or 40°C for 60d, resistant to dessication, pH 2-11, chloroform, ether, alcohol)^{2,14,15,16,17}

Susceptibility

- Wild and laboratory rats
- No strain-dependent susceptibility described¹⁸
- Syrian hamsters and other species such as *Mastomys natalensis* have shown to be susceptible to experimental infection.^{2,19,20}
- Susceptibility greatest *in utero* and in first few days of live; most often results in neonatal loss³

Organotropism

- Viral replication only in mitotically active tissues²¹ such as embryo, intestines, tumours
- Especially proliferating and growing tissues are affected; infection leads to cell destruction.²
- Predilection for the developing liver and cerebellum^{22,23}

Clinical disease

- Most infections are subclinical and asymptomatic^{3,24,25}; clinical disease is a rare event^{2,3}; highly dependent on age at infection.³
- Infection can be severe or lethal, especially in athymic infant rats.²⁶
- Cases of spontaneous clinical disease with deaths have been reported.^{22,27}
- Major effects expected in the fetal development and early life.²
- Fetal deaths and teratologic effects; neonatal abnormalities have been attributed to KRV.^{2,28}
- In pregnant rats increased uterine resorption was observed; with runting, ataxia, cerebellar hypoplasia and jaundice in the litter.²
- Severe disease of rats from birth to several weeks of age (with symptoms such as cerebellar hypoplasia, jaundice, furthermore haemorrhagic infarction with thrombosis in multiple organs incl. brain, spinal cord, testes, epididymidis) observed after natural infection with KRV.²
- Scrotal cyanosis, abdominal swelling, dehydration, other signs of severe illness can occur in juvenile and few weeks old male rats.²
- KRV is known to induce autoimmune diabetes in rats.³
- Cerebellar hypoplasia and ataxia in hamsters after experimental infection²⁹
- Periodontal disease in hamsters²

Pathology

- Focal necrosis, haemorrhage, infarction³
- Haemorrhage and infarction especially in the central nervous system^{23,30,31,32}
- Haemorrhagic encephalopathy reported in adult LEW rats after natural infection²
- Intranuclear parvoviral inclusions in areas of necrosis in clinically affected rats^{3,33}
- Amphophilic intranuclear inclusions in endothelium and other cells of infected organs; focal necrosis, hypertrophy, vascular degeneration of hepatocytes, cholangitis, biliary hyperplasia in the liver²
- Increased leukocyte adhesion in the aortic epithelium³⁴
- Mongoloid-type deformity in new-born hamsters after experimental infection³⁵
- Cerebellar lesions in cats after experimental infection³⁶

Morbidity and mortality

- When rats are newly infected during pregnancy, transmission to progeny is possible and may result in persistent infection of offspring.³⁷
- According to Novotny and Hetrick, experimental infection of females during pregnancy results in up to 100% mortality of the offspring.⁷
- In contrast, when already persistently infected rats are getting pregnant (infection was before pregnancy) they do not produce infected progeny and no mortality was observed after experimental infection of offspring at day 0 or 1.^{7,37}
- Progeny protected from infection presumably by maternal antibodies³⁷
- Transmission of immunity from mother to offspring may lead to latent infections in young rats and support spreading of infection in rat populations.⁷
- Acute disease in hamsters after experimental infection¹⁹

Zoonotic potential

- Not described

Interference with research

Oncology

- Contamination of transplantable or chemically induced tumours^{1,38,39,40}
- Contamination of leukaemias or leukaemia virus preparations^{41,42,43}
- Suppression of leukaemia induction by Moloney virus⁴⁴

Teratology

- Congenital malformation⁴⁵
- Death and resorption of foetuses²²

Infectiology / Interactions with other infectious agents

- Necrosis in the lung may support secondary colonisation with other microorganisms such as *Pasteurella pneumotropica*.⁴⁶
- KRV together with H-1 and *Clostridium piliforme* can influence the prevalence rate of *Yersinia*-induced arthritis in rats.^{47,48}

Immunology

- Infection of T and B lymphocytes and suppression of various lymphocyte functions⁴⁹
- Stimulates autoreactive T lymphocytes specific for pancreatic antigens⁵⁰
- Can cause acute autoimmune diabetes³ or alter susceptibility to autoimmune diabetes in rat strains which are normally resistant to this syndrome (e.g. BB/Wor, LEW1.WR1)^{51,52,53}
- Alters cytotoxic lymphocyte activity⁵⁴
- Depresses lymphocyte viability and a variety of T cell functions like *in vitro* lymphoproliferative responses^{38,39}
- Stimulates interferon production⁵⁵

Toxicology

- No data

Physiology

- Inhibition of lipid formation in rat kidney cells *in vitro*⁵⁶
- Increased abortion rate⁵⁷

Cell biology

- Contaminant of cell lines⁵⁸
- Persistent infection of cell lines and transplantable tumours^{2,59,60}

Assisted reproductive technology

- No data

Special considerations

- No medical treatment described

Actualized by Christina Simon, Basel, December 2021

References

1. Kilham L, Olivier L. 1959. A latent virus of rats isolated in tissue culture. *Virology* 7:428-437.
2. National Research Council. 1991. Committee on Infectious Diseases of Mice and Rats. *Infectious diseases of mice and rats*. Washington, DC: National Academy Press, pp.236-240.
3. Suckow MA, Weisbroth SH, Franklin CL (eds). 2006. *The Laboratory Rat*. American College of Laboratory Animal Medicine Series: Elsevier Academic Press, pp.423-451.
4. Mähler M, Koehl W. 2009. A serological survey to evaluate contemporary prevalence of viral agents and *Mycoplasma pulmonis* in laboratory mice and rats in western Europe. *Lab Anim* 38(5):161-165.
5. Pritchett-Corning KR, Cosentino J, Clifford CB. 2009. Contemporary prevalence of infectious agents in laboratory mice and rats. *Lab Anim* 43(2):165-173.
6. Cagliada MP, Carbone C, Ayala MA, Laborde JM, Maschi F, Milocco SN, Bonzo E, Cid de la Paz V, Galosi CM. 2010. Prevalence of antibodies against Kilham virus in experimental rat colonies of Argentina. *Revista Argentina de Microbiología* 42(1):27-29.
7. Novotny JF, Hetrick FM. 1970. Pathogenesis and Transmission of Kilham Rat Virus Infection in Rats. *Infect Immun* 2(3):298-303.
8. Jacoby RO, Gaertner DJ, Bhatt PN, Paturzo FX, Smith AL. 1988. Transmission of experimentally-induced rat virus infection. *Lab Anim Sci* 38(1):11-14.
9. Robey RE, Woodman DR, Hetrick F. 1968. Studies on the natural infection of rats with the Kilham rat virus. *Am J Epidemiol* 88:139-143.
10. Lipton HG, Nathanson N, Hodous H. 1973. Enteric transmission of parvoviruses. Pathogenesis of rat virus infection in adult rats. *Am J Epidemiol* 6:443-446.
11. Paturzo FX, Jacoby RO, Bhatt PN, Smith AL, Gaertner DJ, Ardito RB. 1987. Persistence of rat virus in seropositive rats as detected by explant culture. *Arch Virol* 95:137-142.
12. Jacoby RO, Johnson EA, Paturzo FX, Gaertner DJ, Brandsma JL, Smith AL. 1991. Persistent rat parvovirus infection in individually housed rats. *Arch Virol* 117:193-205.
13. Gaertner DJ, Jacoby RO, Johnson EA, Paturzo FX, Smith AL. 1995. Persistent rat virus infection in juvenile athymic rats and its modulation by antiserum. *Lab Anim Sci* 45:249-253.
14. Fassolitis AC, Peeler JT, Jones VI, Larkin EP. 1985. Thermal resistance of three parvoviruses: a possible human isolate, the Minute Virus of Mice, and the latent rat virus. *J Food Protect* 48:4-6.
15. Lum GS, Schreiner AW. 1963. Study of a virus isolated from a chloroleukemic Wistar rat. *Cancer Res* 23:1742-1747.
16. Tattersall P, Cotmore SF. 1986. The rodent parvoviruses. In: Bhatt PN, Jacoby RO, Morse HC, New AE (eds.) *Viral and mycoplasmal infections of laboratory rodents. Effects on biomedical research*. Academic Press Inc., Orlando.
17. Yang FC, Paturzo FX, Jacoby RO. 1995. Environmental stability and transmission of rat virus. *Lab Anim Sci* 45:140-144.
18. Jacoby RO, Ball-Goodrich L. 1995. Parvovirus infections of mice and rats. *Sem Virol* 6:329-337.
19. Kilham L. 1961 Rat virus (RV) in hamsters. *Proc Soc Exp Biol Med* 106:825-829.
20. Rabson AS, Kilham L, Kirschstein RL. 1961. Intranuclear inclusions in *Rattus (Mastomys) natalensis* infected with rat virus. *J Natl Cancer Inst* 27:1217-1223.
21. Tennant RW, Hand RE. 1970. Requirement of cellular synthesis for Kilham rat virus replication. *Virol* 42:1054-1063.

22. Kilham L, Margolis G. 1966. Spontaneous hepatitis and cerebellar 'hypoplasia' in suckling rats due to congenital infections with rat viruses. *Am J Pathol* 49:457-475.
23. Cole GA, Nathanson N, Rivet H. 1970. Viral hemorrhagic encephalopathy of rats. II. Pathogenesis of central nervous system lesions. *Am J Epidemiol* 91:339-350.
24. Lum GS. 1970. Serological studies of rat virus in relation to tumors. *Oncology* 24:335-343.
25. Robinson GW, Nathanson N, Hodous J. 1971. Sero-epidemiological study of rat virus infection in a closed laboratory colony. *Am J Epidemiol* 94:91-100.
26. Gaertner DJ, Jacoby RO, Paturzo FX, Johnson EA, Brandsma JL, Smith AL. 1991. Modulation of lethal and persistent rat parvovirus infection by antibody. *Arch Virol* 118:1-9.
27. Coleman GL, Jacoby RO, Bhatt PN, Smith AL, Jonas AM. 1983. Naturally occurring lethal parvovirus infection of juvenile and young-adult rats. *Vet Patho* 20:49-56.
28. Kilham L, Margolis G. 1975. Problems of human concern arising from animal models of intrauterine and neonatal infections due to viruses: a review. I. Introduction and virologic studies. *Progr Med Virol* 20:113-143.
29. Kilham L, Margolis G. 1964. Cerebellar ataxia in hamsters inoculated with rat virus. *Science* 143:1047-1048.
30. El Dadah AH, Nathanson N, Smith KO, Squire RA, Santos GW, Melby EC. 1967. Viral hemorrhagic encephalopathy of rats. *Science* 156:392-394.
31. Margolis G, Kilham L. 1970. Parvovirus infections, vascular endothelium and hemorrhagic encephalopathy. *Lab Invest* 22:478-488.
32. Baringer JR, Nathanson N. 1972. Parvovirus hemorrhagic encephalopathy of rats. Electron microscopic observations of the vascular lesions. *Lab Invest* 27:514-522.
33. Lussier G (ed). 1991. Detection methods for the identification of rodent viral and mycoplasmal infections. *Lab Anim Sci* 41:199-225.
34. Gabaldon M, Capdevila C, Zuniga A. 1992. Effect of spontaneous pathology and thrombin on leukocyte adhesion to rat aortic endothelium. *Atherosclerosis* 93:217-228.
35. Baer PN, Kilham L. 1962. Rat virus and periodontal disease. II. Onset and effect of age at time of inoculation. *Oral Surg Oral Med Oral Path* 15:1302-1311.
36. Kilham L, Margolis G. 1965. Cerebellar disease in cats induced by inoculation of rat virus. *Science* 148:244-246.
37. Jacoby RO, Ball-Goodrich L, Paturzo FX, Johnson EA. 2001. Prevalence of rat virus infection in progeny of acutely or persistently infected pregnant rats. *Comp Med* 51(1):38-42.
38. Campbell Jr DA, Manders EK, Oehler JR, Bonnard GD, Oldham RK, Herberman RB. 1977a. Inhibition of in vitro lymphoproliferative responses by in vivo passaged rat 13762 mammary adenocarcinoma cells. I. Characteristics of inhibition and evidence for an infectious agent. *Cell Immunol* 33:364-377.
39. Campbell Jr DA, Staal SP, Manders EK, Bonnard GD, Oldham RK, Salzman LA, Herberman RB. 1977b. Inhibition of in vitro lymphoproliferative responses by in vivo passaged rat 13762 mammary adenocarcinoma cells. II. Evidence that Kilham rat virus is responsible for the inhibitory effect. *Cell Immunol* 33:378-391.
40. Nicklas W, Kraft V, Meyer B. 1993. Contamination of transplantable tumors, cell lines, and monoclonal antibodies with rodent viruses. *Lab Anim Sci* 43:296-300.
41. Kilham L, Moloney JB. 1964. Association of rat virus and Moloney leukemia virus in tissues of inoculated rats. *J Natl Cancer Inst* 32:523-531.

42. Bergs VV. 1967. Leukemias induced in rats by mammary tumor extracts. *J Natl Cancer Inst* 38:481-490.
43. Spencer HJ. 1967. Recovery of rat virus from a series of chemically induced rat leukemias. *Proc Am Assoc Cancer Res* 8:62.
44. Bergs VV. 1969. Rat virus-mediated suppression of leukemia induction by Moloney virus in rats. *Cancer Res* 29:1669-1672.
45. Margolis G, Kilham L. 1975. Problems of human concern arising from animal models of intrauterine and neonatal infections due to viruses: a review. II. Pathologic studies. *Prog Med Virol* 20:144-179.
46. Carthew P, Gannon J. 1981. Secondary infection of rat lungs with *Pasteurella pneumotropica* after Kilham rat virus infection. *Lab Anim* 15:219-221.
47. Gripenberg-Lerche C, Toivanen P. 1993. Yersinia associated arthritis in SHR rats: effect of the microbial status of the host. *Ann Rheum Dis* 52:223-228.
48. Gripenberg-Lerche C, Toivanen P. 1994. Variability in the induction of experimental arthritis: Yersinia associated arthritis in Lewis rats. *Scand J Rheumatol* 23:124-127.
49. McKisic MD, Paturzo FX, Gaertner DJ, Jacoby RO, Smith AL. 1995. A nonlethal parvovirus infection suppresses rat T lymphocyte effector functions. *J Immunol* 155(8):3979-3986.
50. Brown DW, Welsh RM, Like AA. 1993. Infection of peripancreatic lymph nodes but not islets precedes Kilham rat virus-induced diabetes in BB/W or rats. *J Virol* 67:5873-5878.
51. Guberski DL, Thomas VA, Shek WR, Like AA, Handler ES, Rossini AA, Wallace JE, Welsh RM. 1991. Induction of type 1 diabetes by Kilham's rat virus in diabetes resistant BB/Wor rats. *Science* 254:1010-1013.
52. Stubbs M, Guberski DL, Like AA. 1994. Preservation of GLUT 2 expression in islet beta cells of Kilham rat virus (KR V)-infected diabetes-resistant BB/Wor rats. *Diabetologia* 37:1186-1194.
53. Ellerman KE, Richards CA, Guberski DL, Shek WR, Like AA. 1996. Kilham rat triggers T-cell-dependent autoimmune diabetes in multiple strains of rats. *Diabetes* 45:557-562.
54. Darrigrand AA, Singh SB, Lang CM. 1984. Effects of Kilham rat virus on natural killer cell-mediated cytotoxicity in Brown Norway and Wistar Furth rats. *Am J Vet Res* 45:200-202.
55. Kilham L, Buckler CE, Ferm VH, Baron S. 1968. Production of interferon during rat virus infection. *Proc Soc Exp Biol Med* 129:274-278.
56. Schuster GS, Caughman GB, O'Dell NL. 1991. Altered lipid metabolism in parvovirus-infected cells. *Microbios* 66:134-155.
57. Kilham L, Margolis G. 1969. Transplacental infection of rats and hamsters induced by oral and parenteral inoculations of H1 and rat viruses (RV). *Teratology* 2:111-223.
58. Hallauer C, Kronauer G, Siegl G. 1971. Parvoviruses as contaminants of permanent human cell lines. I Virus isolations from 1960 to 1970. *Arch Ges Virusforsch* 35:80-90.
59. Wozniak J, Hetrick F. 1969. Persistent infection of a rat nephroma cell line with Kilham rat virus. *J Virol* 4:313-314.
60. Bass R, Hetrick FM. 1978. Persistent infection of a human lymphocyte cell line (Molt-4) with the Kilham rat virus. *J Infect Dis* 137:210-212.

Disclaimer

Any use of GV-SOLAS booklets (publications) and statements and the application of the information contained therein are at the express risk of the user. Neither GV-SOLAS nor the authors can accept liability for any accidents or damages of any kind arising from the use of a publication (e.g., resulting from the absence of safety instructions), irrespective of legal grounds. Liability claims against GV-SOLAS and the author for damages of a material or non-material nature caused by the use or non-use of the information or by the use of erroneous and/or incomplete information are in principle excluded. Legal claims and claims for damages are thus excluded. The work, including all content, has been compiled with utmost care. However, GV-SOLAS and the authors assume no responsibility for the currentness, correctness, completeness or quality of the information provided. Printing errors and incorrect information cannot be completely ruled out. GV-SOLAS and the authors accept no liability for the currentness, correctness and completeness of the content of the publications or for printing errors. GV-SOLAS and the authors accept no legal responsibility or liability in any form for incorrect statements and consequences arising therefrom. Responsibility for the content of the internet pages printed in these publications lies solely with the owner of the websites concerned. GV-SOLAS and the authors have no influence on the design and content of third-party websites. GV-SOLAS and the authors therefore distance themselves from all third-party content. Responsibility within the meaning of press legislation lies with the board of GV-SOLAS.